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492Objective: Mitochondrial dysfunction has been suggested as a potential cause for heart failure. Pressure overload
is a common cause for heart failure. However, implementing pressure overload in mice is considered a model for
compensated hypertrophy but not for heart failure. We assessed the suitability of minimally invasive transverse
aortic constriction to induce heart failure in C57BL/6 mice and assessed mitochondrial biogenesis and function.
Methods: Minimally invasive transverse aortic constriction was performed through a ministernotomy without
intubation (minimally invasive transverse aortic constriction, n ¼ 68; sham operation, n ¼ 43). Hypertrophy
was assessed based on heart weight/body weight ratios and histologic analyses, and contractile function was as-
sessed based on intracardiac Millar pressure measurements. Expression of selected metabolic genes was assessed
with reverse transcription–polymerase chain reaction and Western blotting. Maximal respiratory capacity (state 3)
of isolated mitochondria was measured with a Clark-type electrode.
Results: Survival was 62%. Within 7 weeks, minimally invasive transverse aortic constriction induced signifi-
cant hypertrophy (heart weight/body weight ratio: 10.08  0.28 mg/g for minimally invasive transverse aortic
constriction vs 4.66  0.07 mg/g for sham operation; n ¼ 68; P< .01). Fifty-seven percent of mice undergoing
minimally invasive transverse aortic constriction displayed signs of heart failure (pleural effusions, dyspnea,
weight loss, and dp/dtmax of 3114  422 mm Hg/s, P< .05). All of them had heart weight/body weight ratios
of greater than 10. Mice undergoing minimally invasive transverse aortic constriction with heart weight/body
weight ratios of less than 10 had normal contractile function (dp/dtmax of 6471  292 mm Hg/s vs dp/dtmax of
6933  205 mmHg/s in sham mice) and no clinical signs of heart failure. The mitochondrial coactivator perox-
isome proliferator-activated receptor g coactivator alpha (PGC-1a) was downregulated in failing hearts only.
PGC-1a and fatty acid oxidation gene expression were also decreased in failing hearts. State 3 respiration of iso-
lated mitochondria was significantly reduced in all hearts subjected to pressure overload.
Conclusions: Contractile dysfunction and heart failure can be induced in wild-type mice by means of minimally
invasive aortic constriction. Pressure overload–induced heart failure in mice is associated with mitochondrial dys-
function, as characterized by downregulation of PGC-1a and reduced oxidative capacity. (J Thorac Cardiovasc
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The Journal of Thoracic and Cardiovascular SurgPressure overload is one of the most common causes of heart
1failure. Increased workload also increases energy demand.
Recent evidence suggests an important role of metabolic
processes in the development of heart failure. The discussed
mechanisms focus on defects located in the mitochondria.
Reduced expression of the peroxisome proliferator-
activated receptor (PPAR) g coactivator 1a (PGC-1a) during
hypertrophy and heart failure in rats has been demonstrated.2,3
PGC-1a and its homologue, PGC-1b, are metabolic coac-
tivators governing mitochondrial biogenesis and are key
regulators of fatty acid oxidation and oxidative phosphoryla-
tion.4 For the establishment of a causal relationship between
these metabolic alterations and the clinical presentation of
heart failure, genetically altered murine models will be es-
sential and have already been generated.2 However, testing
these genetic variations in models of heart failure results in
2 significant limitations. First, in ischemic heart failureery c February 2011
Abbreviations and Acronyms
ADP ¼ adenosine diphosphate
ATP ¼ adenosine triphosphate
BW ¼ body weight
HW ¼ heart weight
MITAC ¼ minimally invasive transverse aortic
constriction
PCR ¼ polymerase chain reaction
PGC ¼ peroxisome proliferator-activated
receptor g coactivator
PPAR ¼ peroxisome proliferator-activated
receptor
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artery results in postinfarct remodeling, a pathomechanism
completely different from pressure overload. Second, in
the hands of most investigators, pressure overload in wild-
type mice induced by transverse aortic constriction results
in hypertrophy, although not in heart failure with a contractile
dysfunction.
We reasoned that performance of transverse aortic con-
striction without intubation through a partial median sternot-
omy might allow for a tighter constriction, potentially
leading to heart failure and contractile dysfunction in wild-
type mice. We therefore modified a previously reported min-
imally invasive technique3 and assessed its ability to induce
heart failure. We also determined the effect on PGC-1 sig-
naling and mitochondrial respiratory capacity. Our results
demonstrate that minimally invasive transverse aortic con-
striction (MITAC) is suitable to induce heart failure with
contractile dysfunction, which is associated with a downre-
gulation of PGC-1a and fatty acid oxidation gene expres-
sion, as well as reduced oxidative capacity.MATERIALS AND METHODS
Animals
Male C57BL/6 mice (22–24 g, 5–6 weeks of age) were obtained from
Charles River (Sulzfeld, Germany) and were fed ad libitum at 21C with
a light cycle of 12 hours. The use of animals and the experimental protocol
were approved by the Animal Welfare Committees of the Universities of
Leipzig and Freiburg, Germany.
Minimally Invasive Aortic Constriction
The procedure of minimally invasive aortic constriction is a modification
of 2 previously described techniques.3,5 For the banding procedure, mice
were anesthetized with a mixture of ketamine (60–100 mg/kg body weight
[BW] administered intraperitoneally) and xylazine (5–10 mg/kg BW
intraperitoneally), and transverse aortic constriction was performed
through an upper partial sternotomy (0.2–0.3 cm) in spontaneously
breathing nonintubated mice. Particular care was taken not to touch or
damage the parietal pleura to prevent pneumothorax development. The
aortic arch was carefully exposed, and a 5–0 polyviolene suture (Harvard
Apparatus, Holliston, Mass) was used to tightly constrict the aorta between
the brachiocephalic trunk and the left carotid artery over a 29-gaugeThe Journal of Thoracic and Cacannula. After ligation, the cannula was removed to leave an opening not
greater than the diameter of the cannula. In mice undergoing sham
operations the procedure was identical, with the exception of suture
constriction of the aortic arch. Overall mortality was 38% (42/110) in mice
undergoing MITAC and 4% (2/45) in animals undergoing sham operations.
Assessment of Left Ventricular Function
After 7 weeks, all mice were anesthetized with isoflurane, and cardiac
function was evaluated with a 1.4F Millar microtip catheter inserted into
the aorta and the left ventricle through the right carotid artery.6 Aortic
and intraventricular systolic and diastolic pressures were recorded, and
both positive (dp/dtmax) and negative (dp/dtmin) pressure changes over
time were obtained. The rate–pressure product was assessed as the product
of systolic pressure in the aorta and heart rate (expressed as millimeters of
mercury per minute). After invasive measurements, mice were killed by
means of cervical dislocation. Hearts were excised for further analyses.
Isolation of Mitochondria
Tissue homogenization and isolation of mitochondria was carried out as
described previously.7 For isolation of mitochondria, 500 mL of the homog-
enate was centrifuged at 750 rpm for 10 minutes, and the supernatant was
stored in subsarcolemmal mitochondria. The pellet was treated with Na-
garse (5 mg/g wet weight) for 30 seconds and centrifuged at 7000 rpm
for 5 minutes. The resulting pellet was resuspended with KEA (180
mmol/L KCl, 10 mmol/L ethylenediamine tetraacetic acid, and 0.5% albu-
min) and centrifuged at 750 rpm for 10 minutes. The supernatant was trans-
ferred to the tube containing SSM and spun down 3 times at 7000 rpm for 10
minutes. The last pellet was diluted with one third KME (100 mmol/L KCl,
50 mmol/L 3-(N-morpholino)propanesulfonic acid, and 0.5 mmol/L ethyl-
eneglycol-bis-[b-aminoethylether]-N,N,N0,N0-tetraacetic acid) of used ho-
mogenate. All steps were carried out at 4C.
Mitochondrial Respiration
Oxygen consumption of isolated mitochondria was measured at 25C with
a Clark-type oxygen electrode fitted to a water-jacketed reaction chamber of
1 mL in volume.8 Mitochondrial preparations were added to respiration
medium (100 mmol/L KCl; 50 mmol/L 3-(N-morpholino)propanesulfonic
acid; 1.0 mmol/L ethyleneglycol-bis-[b-aminoethylether]-N,N,N0,N0-tetra-
acetic acid; 5.0 mmol/L kaliumphosphate; and 1.0 mg/mL defatted bovine
serum albumin) to a final concentration of 1 U of citrate synthase per milliliter
in the reaction chamber. Maximal oxygen consumption (state 3 respiration),
using glutamate, succinate, pyruvate, or palmitoyl–carnitine as a substrate,
was stimulated by adding 20 mL of adenosine diphosphate (ADP; 10
mmol/L). State 4 respiration was measured as the rate of oxygen consump-
tion after total phosphorylation of added ADP.9 Citrate synthase served as
a mitochondrial marker enzyme and was assessed by using a conven-
tional enzyme assay, as described previously.10
Quantitative Real-Time Reverse Transcription–
Polymerase Chain Reaction
Total RNA from individual murine hearts was isolated with the RNeasy
Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany). Quantitative polymer-
ase chain reaction (PCR) was carried out as described previously.11 In brief,
total RNA (1 mg per sample) was DNase treated and reverse transcribed ac-
cording to the manufacturer’s instructions (Quantitect Rev. Transcription
Kit, Qiagen). For quantitative real-time PCR (Quantitect SyBrGreen Kit,
Qiagen), 20 ng of cDNA and 300 nmol/L sequence-specific primers
(MWG, Ebersberg, Germany) were used. Reactions were run in triplicate
on a MX3000P detector (Stratagene, Amsterdam, The Netherlands). The cy-
cling conditions were as follows: 15 seconds of polymerase activation at
95C and 40 cycles at 95C for 15 seconds, 58C for 30 seconds, and
72C for 30 seconds. The results were analyzed with MxPro software (Stra-
tagene). Results of the genes of interest were normalized with respect tordiovascular Surgery c Volume 141, Number 2 493
TABLE 1. Heart, lung, liver, and body weights and tibia lengths, as
well as the respective ratios from mice undergoing sham operations
and from mice 7 weeks after minimally invasive transverse aortic
constriction
Sham group
(n ¼ 43)
Hypertrophy
group (n ¼ 29)
Heart failure
group (n ¼ 39)
Body weight 25.7  0.45 27.3  0.38y 21.9  1.4y,x
Heart weight 119  2.08 207  6.2y 273  5.34y,x
Heart/body weight 4.66  0.07 7.59  0.2y 12.6  0.26y,x
Ventricle weight 111  2.53 194  7.17y 231  6.26y,x
Ventricle/body weight 4.38  0.06 7.13  022y 10.9  0.46y,x
Lung weight 138  4.24 189  16.7* 433  19.5y,x
Lung/body weight 5.55  0.19 6.94  0.58* 19.7  0.8y,x
Liver weight 1176  37.2 1248  27.8 917  32y,x
Liver/body weight 47  1.24 45.8  0.75 41.5  1.28y,x
Tibia length 18  0.05 18.3  0.06y 18  0.11z
Tibia/body weight 0.7  0.01 0.66  0.01 0.84  0.03y,x
Values are means  standard errors of the mean. *P< .05 and yP< .01 versus the
sham group. zP< .05 and xP< .01 versus the hypertrophy group. Mice undergoing
minimally invasive transverse aortic constriction were separated into a hypertrophy
group and a heart failure group based on their heart weight/body weight ratios (see
text for details).
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time reverse transcription PCR are listed in Table E1.
Western Blots
For Western blot analysis, protein concentration of homogenized tissue
was measured according to the Bradford method. Protein (maximum of
25 mg) was loaded in each slot of a 15% polyacrylamide gel and separated
at 120 mA for 1 hour. Separated proteins were transferred to a polyvinyli-
dene fluoride membrane (Millipore, Schwalbach, Germany). Membranes
were washed with TBS-T (0.15 mol/L NaCl, 0.05 mol/L Tris, and 0.1%
Tween) and blocked with 5%milk for 1 hour at room temperature. Incuba-
tion with primary antibody in TBS-T with 5% bovine serum albumin was
done overnight at 4C. The primary antibody, OXPHOS Rodent Antibody
Cocktail MS604, was purchased from Mito Science (Eugene, Ore) and used
at a final dilution of 1:500. The secondary antibody, anti-mouse NXA931,
was purchased from GE Healthcare (Fairfield, Conn) and used at a final di-
lution of 1:40,000 in TBS-T. In the case of PGC-1a, the primary antibody
was purchased from Calbiochem (San Diego, Calif; no. 516557) and used at
a final dilution of 1:1000. The secondary antibody, anti-rabbit A6154, was
purchased from Sigma-Aldrich (St Louis, Mo) and used at a final dilution of
1:10,000 in TBS-T. Membranes were incubated for 1 hour with secondary
antibody at room temperature. After incubation, 6 washing steps of
10 minutes followed. Immunoreactive bands were detected with ECL re-
agent (solution A: 100 mmol/L Tris [pH 8.5], 2.5 mmol/L luminol, and
0.4 mmol/L cumaric acid; solution B: 100 mmol/L Tris [pH 8.5] and
1.5% H2O2) and exposed to Hyperfilm (GE Healthcare).
Histologic Assessment
For histologic assessment, hearts were fixed with 4% paraformaldehyde
in phosphate-buffered saline, embedded in paraffin, and stained with hema-
toxylin and eosin. Left ventricular myocyte cross-sectional areas were ana-
lyzed by means of computer-assisted morphometry.12
Statistical Analysis
Values are presented as means  standard errors of the mean. Data were
analyzed by using a 1-way analysis of variance test, followed by post hoc
analysis with the Newman–Keuls test.
RESULTS
Heart/Body Weight Ratios Correlate With
Contractile Function and Markers of Heart Failure
Table 1 shows heart weight (HW), lung weight, liver
weight, body weight (BW), tibia length, and the isolated or-
gan weights and tibia length/BW ratios of mice undergoing
sham operations and mice undergoing minimally invasive
aortic constriction. All mice with constriction of the aorta
had significant hypertrophy (HW/BW ratio: 10.08  0.28
mg/g for MITAC vs 4.66  0.07 mg/g for sham, P< .01).
Fifty-seven percent of these mice had clinical signs of heart
failure. All of them had HW/BW ratios of greater than 10.
Mice with suspected heart failure showed lower levels of
spontaneous locomotor activity, dyspnea, and rough fur.
The onset of heart failure was associated with dramatic in-
creases in lung weight and lung weight/BW ratios.
Figure 1, B, shows the relationship between HW/BW ratios
and lung weight. At an HW/BW ratio of greater than 10,
there is an abrupt and consistent increase in lung weight. Af-
ter opening the thorax for organ harvesting, all animals with
these symptoms had significant pleural effusions. These494 The Journal of Thoracic and Cardiovascular Surgsigns were practically absent in animals with HW/BW ratios
of less than 10. We used these observations to separate the
MITAC mice into 2 groups, those with compensated hyper-
trophy (HW/BW ratio<10) and those with heart failure
(mice undergoing MITAC with HW/BW ratios>10).
Figure 1, A, shows representative histologic stains of
myocardial cross-sections from hearts of animals undergo-
ing sham operations or from animals having undergone
MITAC having either compensated hypertrophy or heart
failure. Hearts with compensated hypertrophy were mainly
characterized by increased cardiac mass caused by an in-
crease in wall thickness. Hearts having hypertrophy with
failure also displayed increased mass, but wall thickness
was less than in the compensated group, and the left ventric-
ular cavity was dilated. Figure 1, C and D, shows the expres-
sion of commonly accepted heart failure marker genes in
heart tissue from animals undergoing sham operations or an-
imals undergoing MITAC having hypertrophy with normal
contractile function or heart failure. Although atrial natri-
uretic peptide, brain natriuretic peptide, and b-isoform of
the myosin heavy chain levels were only mildly increased
in the hypertrophy group, the values were dramatically in-
creased when clinical signs of heart failure were present.
The expression of calcium adenosine triphosphatase of the
sarcoplasmic reticulum II was already reduced in the hyper-
trophied hearts, but the greatest reduction in expression was
found in failing hearts.
Table 2 shows the results of the invasive pressure mea-
surements by using the Millar catheter. Heart rate was lowest
in the heart failure group. Hypertrophied hearts generated
the highest blood pressure, whereas diastolic blood pres-
sures were similar in all groups. Hypertrophied hearts withery c February 2011
FIGURE 1. A, Histologic stains of representative hearts from animals undergoing sham operations (left image) or from animals undergoing minimally in-
vasive transverse aortic constriction with either compensated hypertrophy (middle image) or heart failure (right image). B, Lung weight as a function of heart/
body weight ratio. C and D, Expression of heart failure markers in heart tissue from animals undergoing sham operations or animals undergoing minimally
invasive transverse aortic constriction having hypertrophy with normal contractile function or heart failure. C, Atrial natriuretic peptide (ANP), brain natri-
uretic peptide (BNP), b-isoform of the myosin heavy chain (b-MHC; n ¼ 5 per group). D, Calcium adenosine triphosphatase of the sarcoplasmic reticulum II
(SERCA 2a; n ¼ 5 per group). *P< .05 and **P< .01 versus the sham group. #P< .05 and ##P< .01 versus the hypertrophy group.
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of contractile dysfunction. The rate–pressure product was
significantly increased, and dp/dtmax and dp/dtmin values
were normal. In the heart failure group the rate–pressure
product, dp/dtmax, and dp/dtmin were significantly reduced,
indicating the presence of contractile dysfunction.The Journal of Thoracic and CaRespiratory Capacity Is Impaired in Isolated
Mitochondria From Hypertrophied and Failing
Hearts
Figure 2 shows the results of the respiratory capacity
assessment of isolated mitochondria with a Clark-type elec-
trode. Four different substrates were used to assess therdiovascular Surgery c Volume 141, Number 2 495
TABLE 2. Assessment of contractile function by means of Millar
catheter measurement in hypertrophied, failing, and control hearts
(sham operations) after minimally invasive transverse aortic
constriction
Sham group
Hypertrophy
group
Heart failure
group
Heart rate (beats/min) 566  15 543  29 423  43*,z
Systolic blood
pressure (mm Hg)
96  2 144  7y 105  11x
Diastolic blood
pressure (mm Hg)
57  3 63  2 61  7
dp/dtmax (mm Hg/s) 6933  205 6339  301 3114  422y,x
dp/dtmin (mm Hg/s) 6498  232 6433  412 2263  703y,x
Rate–pressure product 53,977  1496 74,553  3280y 44,377  6228x
Values are means  standard errors of the mean (n ¼ 4–16 per group). *P< .05.
yP< .01 versus the sham group. zP< .05. xP< .01 versus the hypertrophy group.
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ducing equivalents through the glucose oxidation pathway
(pyruvate), the fatty acid oxidation pathway (palmitoyl–
carnitine), or parts of the citric acid cycle (glutamate and suc-
cinate). There was a significant reduction in respiratory
capacity of mitochondria from both hypertrophied and fail-
ing hearts compared with that seen in hearts undergoing
sham operations with all substrates. Total activity with succi-
nate (delivering mainly flavin adenine dinucleotide reduced)
was 4-fold greater than with glutamate as substrate (deliver-
ing mainly b-nicotinamide adenine dinucleotide). Maximal
total activity with the glucose and fatty acid oxidative
substrates palmitoyl–carnitine and pyruvate (resulting in
a mix of b-nicotinamide adenine dinucleotide and flavin ad-
enine dinucleotide reduced delivery to the respiratory chain)
was more than with glutamate but less than with succinate as
substrates.
Assessing respiratory capacity in isolated mitochondria
also provides information on the coupling of adenosine
triphosphate (ATP) production to oxygen consumption.
Table E2 shows the ADP per oxygen ratios of the 3 groups
for the 4 substrates used. Although the ADP per oxygen ratios
were greater than 2 in the animals undergoing sham opera-
tions for all substrates, pressure overload caused an almost
uniform significant reduction in this coupling ratio, indicating
a loss of efficiency in ATP production not only in the failing
hearts but also already in clinically compensated hypertrophy.
PGC-1a Expression and Downstream Targets Are
Reduced in Pressure Overload–Induced Heart
Failure
The top panel of Figure 3 shows the expression of the 2
metabolic coactivators PGC-1a and PGC-1b. Although in
the hypertrophy group expression levels were normal,
PGC-1a expression (both mRNA and protein) was signifi-
cantly reduced in the failing hearts.
The bottom panel of Figure 3 shows the expression of
downstream targets of PGC-1a and PGC-1b (ie, the nuclear496 The Journal of Thoracic and Cardiovascular Surgtranscription factor PPARa), genes of the fatty acid oxida-
tion machinery (cluster of differentiation 36 [CD36], carni-
tine O-palmitoyltransferase 1 [CPT1], long-chain acyl
coenzype A dehydrogenase [LCAD], and medium chain
acyl CoA dehydrogenase [MCAD]). There was a trend to-
ward reduced expression of the fatty acid oxidation machin-
ery in mice undergoing MITAC, which was consistent with
an early significant reduction in the expression of its tran-
scription factor, PPARa. Assessment of Cdk9 expression,
a recently described potential suppressor of PGC-1a,13 re-
vealed an unexpected downregulation in the heart failure
group.
Gene and protein expression of the respiratory chain com-
plexes (I-V) are shown in Table E3. The expression of the
complexes did not show a clear trend. Complex I expression
was lowest in mice with hypertrophy and heart failure, but
the differences were only significantly lower for protein
expression in the hypertrophy group. Complexes III, IV,
and V had normal mRNA but reduced protein expression
in the heart failure group compared with those seen in
control mice.
DISCUSSION
We demonstrate in this study that MITAC is able to in-
duce heart failure in wild-type mice. As expected, this pres-
sure overload–induced heart failure is associated with
a downregulation of PGC-1a and fatty acid oxidation gene
expression and reduced oxidative capacity.
The novel observation in this study is the inducibility of
heart failure by MITAC in a wild-type mouse. Our ability
to induce heart failure with pressure overload in wild-type
mice allowed us to assess the relevance of commonly dis-
cussed metabolic pathomechanisms for the onset of pressure
overload–induced heart failure. Although our findings are in
general consistent with the common notions, some of our
observations do not completely fulfill the expectations and
require further discussion.
One suggested metabolic mechanism for the development
of heart failure is a maladaptive downregulation of PGC-1a.3
If PGC-1a, the coactivator and therefore regulator of the tran-
scription factors for respiratory chain and fatty acid oxidation
gene expression,14 is downregulated, it is easily envisioned
that the ability to produce ATP is decreased. We find less
PGC-1a and less fatty acid oxidation gene expression, but
the expression of both respiratory chain mRNA and protein
is not uniformly decreased in the failing hearts. In addition,
in the hypertrophied hearts with normal function, in which
PGC-1a expression is normal, there is evidence for mito-
chondrial dysfunction and a significant downregulation of
PPARa (the key transcription factor for fatty acid oxida-
tion15). These observations are not fully consistent with the
hypothesis that PGC-a is the cause for these alterations.
PGC-a might therefore not be the only culprit, and other
regulatory mechanisms might be additionally involved. Theery c February 2011
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FIGURE 2. State 3 respiration of isolated mitochondria from animals undergoing sham operations and animals undergoing minimally invasive transverse
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hypertrophied and failing hearts at almost normal protein
levels might suggest that the regulation of the respiratory
complexes could be defective and not merely the expression
of the machinery. A recent investigation in dogs with
microembolization-induced heart failure demonstrated
defects in the formation of respiratory supercomplexes, ex-
plaining mitochondrial dysfunction at normal protein expres-
sion.16 Whether this mechanism also accounts for our
findings remains to be determined.
Nevertheless, the in vitro assessment of state 3 respiration
allows the identification of potential sites of dysregulation.
We found decreased state 3 respiration in cases of both hy-
pertrophy and heart failure with all substrates. This finding
supports the notion that a reduction in ATP-producing ca-
pacity might be a cause for the onset of heart failure.17 Tak-
ing a close look at the total activities achieved with the
different substrates might help to identify the rate-limitingThe Journal of Thoracic and Casteps. Total respiratory capacity in animals undergoing
sham operations with glutamate as a substrate resulted in
a value of around 350 nanoatoms of oxygen per milligram
of protein. The same value with succinate as a substrate
was 4 times greater, suggesting a lower catalytic capacity
of complex I compared with the downstream complexes in
the chain. The effects of the banding procedure affected all
substrates similarly, and the lowest values were again found
with glutamate as a substrate. The reduced values in hyper-
trophied and failing hearts with succinate were similar to the
sham values with glutamate as a substrate, suggesting that if
a reduction in respiratory capacity is responsible for the on-
set of heart failure, the rate-limiting step, and therefore the
potential culprit, might be found at the level of complex I.
This conclusion would be consistent with our findings in
rats in which we identified a specific complex I defect as
a potential cause of decreased respiratory capacity (unpub-
lished observations, 2009).rdiovascular Surgery c Volume 141, Number 2 497
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FIGURE 3. Top panels, mRNA (n¼ 5 per group; A) and protein expression (n¼ 10–12 per group; B) of PGC-1a and PGC-1b in cardiac tissue from animals
undergoing sham operations and animals undergoing minimally invasive transverse aortic constriction having hypertrophy with normal contractile function or
heart failure separated by the heart/body weight ratio. S29/a-tubulin was used as a housekeeping gene/protein after stable expression under current conditions
was established. Bottom panels, mRNA expression of downstream targets of PGC-1a. Genes involved in fatty acid oxidation: PPARA (A), MCAD (B) and
LCAD (C), CD36 (D), CPT1 (E), and the upstream PGC-1a regulator CDK9 (F) in cardiac tissue from animals undergoing sham operations and animals
undergoing minimally invasive transverse aortic constriction having hypertrophy with normal contractile function or heart failure separated by the heart/
body weight ratio. S29 was used as housekeeping gene after stable expression of this gene under the current conditions was established (n ¼ 5 per group).
*P< .05 and **P< .01 versus the sham group. #P< .05 and ##P< .01 versus the hypertrophy group.
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above-mentioned PGC-1a hypothesis, they provide sub-
stantial support for it and do not reject it. Others have already
demonstrated in PGC-1a–null mice with heart failure on
aortic constriction that reintroduction of the PGC-1a con-
struct and re-expressing it resulted in a delay in the onset
of contractile dysfunction.2 Although the authors thereby
demonstrated the pharmacologic potential of PGC-1 overex-
pression, the causal link between PGC-1a downregulation
and the onset of heart failure has not yet been established.
Overexpression of PGC-1a in mice not undergoing aortic
constriction results in heart failure, possibly through the
massive amounts of PGC-1a protein present in these
hearts.14 The effects of overexpressing PGC-1a in mice
with heart failure is currently under investigation.
The finding of impaired mitochondrial function in the face
of contractile dysfunction has led to the speculation of a po-
tential causal relationship between the two. The first meta-
bolic derangement that was identified in heart failure was
a downregulation of fatty acid oxidation gene expression.18
Our results support this notion, suggesting that the impair-
ment of mitochondrial function (ie, ATP-producing capac-
ity) is unable to support the increased energy demand by
the hypertrophied contractile apparatus and increased work
load. It is interesting to note in this context that many patho-
logical signaling pathways activate hypertrophic growth but
inhibit mitochondrial biogenesis.19 We believe that a balance
between hypertrophic growth and mitochondrial function is
required for physiological hypertrophy and that heart failure
ensues once a dysbalance arises. This hypothesis is supported
by the findings of contractile dysfunction in animal models
with overexpression of either activators of mitochondrial
biogenesis20 or stimulators of hypertrophic growth21 and is
currently the mainstay of our experimental work.
This report is the first to demonstrate the reproducible
induction of heart failure by minimally invasive induction
of pressure overload. Previous investigations describe
models in which pressure overload only causes hypertro-
phy3 or in which intubation was required.22 Rothermel
and colleagues23 describe a method to induce contractile
dysfunction in mice with conventional transverse aortic con-
striction. In this report the authors tie a suture over a 28-
gauge needle. However, the mortality rate was 52% within
the first week. We modified a previously described mini-
mally invasive technique by using a woven suture rather
than a monofilament suture and tied over a 29-gauge instead
of a 27-gauge cannula. We achieved 62% survival over 7
weeks. Although we did not aim to compare our MITAC ap-
proach with conventional transverse aortic constriction, it
might be reasoned that the lower surgical mortality in our
approach excludes significant disadvantages of the mini-
mally invasive exposure.
Another investigation reported evidence for contractile
dysfunction in mice with aortic constriction.24 TheseThe Journal of Thoracic and Cainvestigators applied a much thinner monofilament suture
to the aortic arch in intubated mice and experienced a striking
phenomenon in some of their animals. The suture was inter-
nalized into the aortic arch without interruption of aortic
continuity leaving the animals free of signs from pressure
overload.25 In our hands all animals had hypertrophy, and
more than half of them had heart failure.
We identified the HW/BW ratio together with increased
lung weights as simple but effective markers to distinguish
between the mice with compensated hypertrophy and heart
failure. In addition, this by default postmortem observation
correlates relatively well with the clinical presentation of
the mice. Those with heart failure can easily be identified
by means of observation of the BW and the activity and
breathing patterns in the cage. The mice with heart failure
begin to lose weight at the end of the observation period
of 7 weeks, whereas the others continue to grow. This find-
ing is subtle by looking at the BWs in Table 1 but is easily
visible looking at the individual weight records for each
mouse. Thus our method of minimally invasive aortic con-
striction reproducibly induces heart failure in a significant
fraction of mice that can be identified by means of simple
in vivo and postmortem parameters.
As a limitation to our study, we were not able to measure
pressure gradients across the constricted aorta. Especially in
animals with severe heart failure, a prolonged measurement
was not possible because of their poor clinical condition. It
would be interesting to assess cardiac function in vivo
with echocardiographic analysis in the future.
In conclusion, we demonstrate in this study that MITAC
can be applied to induce heart failure with contractile dys-
function in wild-type mice. This pressure overload–induced
heart failure is associated with a downregulation of PGC-
1a and fatty acid oxidation gene expression and reduced
oxidative capacity.References
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TABLE E1. Primer and probe sequences and accession numbers of
genes used for quantification of mRNA levels by means of real-time
reverse transcription–polymerase chain reaction
Gene Forward/reverse primer sequence
Nppa GCTTCCAGGCCATATTGGAG/
GGGGGCATGACCTCATCTT
NM_008725.2
Nppb CCCAAAAAGAGTCCTTCGGTC/
CGGTCTATCTTGTGCCCAAAG
NM_008726.3
Myh7 ACTGTCAACACTAAGAGGGTCA/
TTGGATGATTTGATCTTCCAGGG
NM_080728.2
Atp2a2 GAGAACGCTCACACAAAGACC/
CTTCTTCAGCCGGCAATTCGTTG
NM_009722.2
Ppargc 1a GAAAGGGCCAAACAGAGAGA/
GTAAATCACACGGCGCTCTT
NM_008904.1
Ppargc 1b TTCCTCAACTATCTCTCTGACACG/
TCTGGCAAGTCAGCACACA
NM_133249
Ppara CCGAGGGCTCTGTCATCA/
GGGCAGCTGACTGAGGAA
NM_011144
Acadm CTGATGAGGGACGCCAAG/
TCAATGTGCTCACGAGCTATG
U07159
Acadl TGGTGGGGACTTGCTCTC/
GTGCAATTGGAGTACGCTTG
U21489
Cd36 TGAAAAGTCTCGGACATTGAGA/
CAGATCCGAACACAGCGTAG
NM_007643
Cpt1b CGTCACTGCCTAAGCTTCCT/
CCGCACAGAATCCAAGTACC
NM_009948
CDK9 AAGCCAAGCACCGTCAGA/
AGGCTGTGATGGGGAACC
NM_130860
Ndufa12 TGGTGGAGGTCCTGAAGC/
CCCACCAGTGTACCAATCCT
BC086922
Sdhb GGAGGGCAAGCAACAGTATC/
ACTCGTACAGCCCGTCCA
BC051934.1
Uqcrc2 AAGGCATTCGGAGTGATATTG/
AACTCGGGTGCTGTGGTG
NM_025899
Cox5a TTAAATGAATTGGGAATCTCCAC/
GTCCTTAGGAAGCCCATCG
NM_007747
Atp5b GCCAAGATGTCCTGCTGTTTA/
CCCAATAAGGCAGACACCTC
BC037127
Rps29 ATGGGTCACCAGCAGCTCTA/
AGCCTATGTCCTTCGCGTACT
NM_0099093.1
TABLE E2. ADP/O ratios of isolated cardiac mitochondria in animals
undergoing sham operations and animals undergoing minimally
invasive transverse aortic constriction having hypertrophy with
normal contractile function or heart failure
ADP/O
Respiratory substrate
Sham
group
Hypertrophy
group
Heart failure
group
Glutamate 2.03  0.12 1.32  0.10y 1.60  0.06*
Succinate 2.27  0.19 1.65  0.21* 1.59  0.16*
Palmitoyl-carnitine/malate 2.11  0.13 1.56  0.33 1.31  0.16y
Pyruvate/malate 2.33  0.11 2.58  0.54 1.93  0.19
Values are means  standard errors of the mean (n ¼ 4–12 per group). *P< .05 and
yP< .01 versus the sham group.
TABLE E3. mRNA and protein expression of the respiratory chain
complexes I to V from animal undergoing sham operations and
animals undergoing minimally invasive transverse aortic constriction
having hypertrophy with normal contractile function or heart failure
Expression
Sham
group
Hypertrophy
group
Heart failure
group
mRNA
Complex I 1  0.55 0.49  0.07 0.35  0.05
Complex II 1  0.25 1.17  0.11 0.71  0.08
Complex III 1  0.19 1.28  0.36 0.97 0.15
Complex IV 1  0.30 1.42  0.64 1.37  0.69
Complex V 1  0.35 0.97  0.18 0.90  0.13
Protein
Complex I 1  0.11 0.61  0.07* 0.64  0.14
Complex II 1  0.10 0.75  0.20 0.65  0.13
Complex III 1  0.14 1.23  0.27 0.54  0.06*
Complex IV 1  0.10 0.74  0.17 0.67  0.11*
Complex V 1  0.09 1.41  0.26 0.67  0.06*
Values are means  standard errors of the mean (n ¼ 5–6 per group). mRNA expres-
sion was normalized to S29 as the housekeeping gene, and protein expression was nor-
malized to a-tubulin. *P< .05 versus the sham group.
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